

1 **Supplementary material to**

2 **Parent perspectives on complex needs in patients with MCT8 deficiency: an international,**
3 **prospective, registry study**

4 Ferdy S. van Geest, Stefan Groeneweg, Veronica M. Popa, Milou A.M. Stals, W. Edward Visser

5

6 **Supplementary material**

7 **Registration in the International MCT8 Deficiency Registry**

8 Upon registration, parents/caregivers (from here on: collectively termed parents) were asked to
9 provide informed consent via a digital informed consent form (see section 'Informed consent form').
10 After providing full informed consent, the questionnaire for parents was made available to the parents
11 (see section 'Questionnaire for parents'). Moreover, the parents received a unique token to provide to
12 their caregiving physician. With this token, the caregiving physician was able to register in the system
13 and received access to the questionnaire for physicians (see section 'Questionnaire for physicians')
14 upon registration. Without this token, physicians were not able to enter the registry and to provide
15 data, thereby preventing physicians from sharing data from their patient(s) without full informed
16 consent from the parents. In case the parents did not provide full informed consent, no questionnaires
17 were sent out and no data was collected. In case parents retracted full informed consent, data on the
18 patient was deleted from the registry. With no formal patient organization existing when the registry
19 was designed, we consulted several members of the parent community on the design of the
20 questionnaires for parents and physicians prior to implementation in the registry, with the goal to
21 capture relevant data as efficient as possible. The questionnaires for parents and physicians could be
22 sent out periodically, to ensure data was updated. The informed consent form, questionnaire for
23 parents and questionnaire for physicians were available in the English, Dutch and Italian languages.

24 **Technical details of the International MCT8 Deficiency Registry**

25 Questionnaires were developed in LimeSurvey (LimeSurvey GmbH, Hamburg, Germany). Audit
26 tracking software monitored access patterns, machine locations and user IDs in the registry. This
27 information enabled accurate tracking and identifying any illegal usage. The registry stored some user
28 information so that it could act as a register of users, and logged the user's IP address (automatically
29 recognised by the web server). The website and server logs were hosted by the IT Services at the
30 Erasmus Medical Center using private, TLS-encrypted web browser sessions, and the IP information

31 was accessed through tools provided by Google Analytics. Cookies were not used for collecting user
32 information from the site and did not collect any information about users except that required for
33 conducting research using data gathered in the registry, enforcing privacy rules of the registry, or for
34 system administration of the registry.

35 Access to all information in the registry was tightly controlled with passwords and logins set at multiple
36 levels. User passwords were acquired and stored encrypted using a one-way hash function, ensuring
37 that passwords could not be extracted from the password database. Access to the registry was limited
38 to named people who have specific job responsibilities related to the registry. The registry was housed
39 within the Erasmus Medical Center IT services and all project staff within the organization undertook
40 training in the protection of data confidentiality.

41 **Data handling, cleaning and validation**

42 Data of patients of whom parents provided full informed consent and at least one answer to the
43 questionnaire for parents was exported from the International MCT8 Deficiency Registry. Obvious
44 erroneous data (e.g. age at diagnosis older than current age) was verified with parents or physicians
45 and corrected if needed, prior to analyses. In case answers were provided in another language than
46 English, answers were translated to English prior to categorization (using online available translation
47 tools). Explicit consent of parents was asked and provided for all quotes. Patients with missing data
48 were excluded from individual analyses to minimize confounding effect.

49 **Sensitivity analyses**

50 Analyses of median diagnostic delay were performed descriptively after stratification by continent of
51 residence. Sensitivity analyses on diagnostic delay were performed after exclusion of patients born
52 before the first report on MCT8 deficiency in October 2004 (1, 2).

53 **Informed consent form**

54 The informed consent form consisted of the following sections. Every item in the informed consent
55 section requires choice of a preset answer ('yes' or 'no').

56 **Patient identification**

- 57 - First name patient
- 58 - Last name patient
- 59 - Date of birth patient

60 **Informed consent**

- 61 - I understand that my participation in the registry is voluntary and that I can change my mind
62 and withdraw at any time.
- 63 - I understand and consent that the doctor will be asked to provide information from the
64 patient's records.
- 65 - I understand that all attempts will be made to protect my privacy and my family's privacy. I
66 understand that my personal information will be protected and saved in the registry using a
67 code. However, there is a very small risk that my personal information could be revealed.
- 68 - I understand that by agreeing to participate, I will be contacted by the registry to update or
69 correct my health information regularly.
- 70 - I understand that I will be contacted by e-mail.
- 71 - I am willing to provide my de-identified medical information to be used for clinical trials and
72 other medical studies related to my disease.
- 73 - I understand that my de-identified information can be used for any approved research study
74 including diseases that are not associated with my disease.
- 75 - I understand that my de-identified information may be shared with other databases such as
76 the Global Rare Disease Patient Registry and Data Repository (GRDR).
- 77 - I understand that I may not personally benefit from participating in the registry or from the
78 use of my de-identified medical information in any research study.
- 79 - I understand that I can withdraw from the registry at any time and remove my information. I
80 also understand that any information given previously and already have been assigned to a
81 specific study, cannot be removed.
- 82 - If permitted, I would like to know of any findings or results that may affect my child's or family
83 member's health.
- 84 - I would like to be contacted of any future clinical trials or other studies that I can participate
85 in.

86 Questionnaire for parents

87 The questionnaire for parents consisted of the following sections. The questionnaire includes closed
88 questions (preset answer options: *yes, no, or no answer*; other preset answer options are shown in
89 *italic* below, where applicable) and open questions. For some questions, multiple present answers can
90 be chosen (indicated with *o* below). Explanatory information is provided in the system to further clarify
91 questions. Parents can remark on their answers for a subset of questions. The sections 'Medical
92 history', 'Current medication', 'Progression of symptoms' and 'Progression of symptoms' include user-
93 friendly tables to enable easy data entry.

94 General information

- 95 - Date of birth of your child?
- 96 - Age at which MCT8 deficiency was diagnosed? (years and months)
- 97 - Are any other family members also affected?
- 98 - Please specify who and the family relation to your child.
- 99 - Is mother a known carrier of the MCT8 mutation?
100 *Yes; No; Not tested*
- 101 - What is the highest education level of father?
102 *No education; Primary school; Secondary school (middle / high school); Community*
103 *college; University*
- 104 - What is the highest education level of mother?
105 *No education; Primary school; Secondary school (middle / high school); Community*
106 *college; University*

107 Pregnancy and delivery

- 108 - Gestational age at time of delivery? (weeks and days)
- 109 - Have any prenatal screenings been performed?
- 110 - Please specify the prenatal tests and describe abnormal findings (if applicable).
- 111 - What was the birth weight (in grams)?
- 112 - What was the birth length (in centimeters)?

113 Growth and development

- 114 - At what age did you first realize that something was wrong with the development of your
115 child?
- 116 - What was/were the first sign(s)/symptom(s)?
- 117 - How did these signs and symptoms progress during the first year of life?
- 118 - What difficulties did you encounter in the diagnostic trajectory?
- 119 - Development of motor milestones (current situation). Please provide age when milestone was
120 first reached (in years).
 - 121 Slippis not through
 - 122 Maintains head balance in sitting position
 - 123 Turns head around

- 124 ○ Lifts head while lying on his belly
- 125 ○ Reach/slap to toys or things
- 126 ○ Grasp to / hold toys or things
- 127 ○ Turns from back to belly
- 128 ○ Turns from belly to back
- 129 ○ Sits in tripod
- 130 ○ Sits without support
- 131 ○ Crawls
- 132 ○ Stands with support
- 133 ○ Stands without support
- 134 ○ Walks with support
- 135 ○ Walks without support
- 136 ○ Jumps
- 137 ○ Cycles
- 138 ○ None of the above
- 139 - Development of fine motor milestones (current situation). Please provide age when milestone
- 140 was first reached (in years).
- 141 ○ Fixates with eyes on object
- 142 ○ Grasps object
- 143 ○ Grasps objects and puts in his mouth
- 144 ○ Moving object from one hand to the other
- 145 ○ Drinks with a cup
- 146 - Is there progression in the abovementioned motor skills?
- 147 - Did your child loose the ability to do things he was able to do before?
- 148 - Development of social/communication skills (current situation). Please provide age when
- 149 milestone was first reached (in years).
- 150 ○ Cry
- 151 ○ Smile
- 152 ○ Monotonic sounds
- 153 ○ Combination of sounds
- 154 ○ Babbling
- 155 ○ First words
- 156 ○ Combination of words
- 157 - Is there progression in the abovementioned communication skills?
- 158 - Did your child loose the ability to do things he was able to do before?
- 159 - How do you predominantly communicate with your child?
- 160 - Do you have the impression your child has any visual problems?
- 161 - Do you have the impression your child has any hearing problems?
- 162 - Do you have the impression your child is able to taste different flavours?
- 163 - Is your child able to let you know whether he likes or dislikes something?
- 164 - Does your child respond to pain (e.g. during blood sampling, biting on his hand/lips)?
- 165 - How was your child fed during the first 0-6 months of life?
- 166 *Breast fed; With a bottle; Other way of feeding*
- 167 - Were any feeding problems present at that time?
- 168 - Please specify what kind of feeding problems were present?
- 169 - Does your child currently aspirate any food?
- 170 - If yes, what kind of food does your child currently aspirate?
- 171 *Liquid; Smooth/pureed; Pieces/chopped; Solid*
- 172 - How frequently does your child aspirates food?
- 173 *Multiple times a day; Once a day; Less than twice a week*
- 174 - Does your child has a PEG tube / gastrostomy or an intranasal feeding tube?
- 175 *No; Intranasal feeding tube; PEG tube / gastrostomy*

176 - Does your child have gastric reflux?

177 **Sleeping**

178 - Does your child have difficulties to fall asleep (takes > 30 minutes)?

179 - Describe your child's sleeping pattern at night?

180 *Sleeps whole night; Wakes up 1 x; Wakes up 2-5x; Wakes up more than 5x*

181 - Time of awakening during the night (between 10 pm and 7 am)?

182 *Before 4AM; After 4AM; Both*

183 - Describe the behaviour when your child is awake during the night?

184 - Does your child sleep during daytime more than 3 days a week?

185 **Thyroid Hormone**

186 - Does your child easily sweat during minor exercise?

187 - Does your child easily loose weight during periods of infections or increased stress?

188 - Does your child have difficulties to (re)gain weight?

189 - Does your child easily get agitated?

190 - Does your child have frequent stools (>4 times a day)?

191 **Medical History**

192 - Please list the medical history of your child (e.g. severe illness requiring hospital admission,
193 surgery, recurrent infections etc.)?

194 - Health care use: please indicate which doctors you regularly visit.

195 **Current medication**

196 - Please indicate the current medication of your child.

197 **Supporting care and devices**

198 - Please check the supporting care your child gets at the moment and further specify your
199 experiences.

200 Physical therapy

201 Horse riding therapy

202 Speech therapy

203 Music therapy

204 Dietary advice

205 Swimming

206 Other

207 - Please check what kind of supporting devices your child uses at the moment and further
208 specify what your experiences are.

209 Wheelchair

210 Standing frames

211 Walkers and gait trainers

212 Tricycle

213 Other devices used to promote mobilization

214 Splints

215 Brace/corset

216 Speech computer

217 Eye gazer

218 Other devices used to promote communication

219 Other

220 **General questions**

- 221 - What is the living situation of your child?
222 *At home; Other; In an institution; Combination of both*
- 223 - List the top 3 major problems you encounter in the daily care for your child due to the disease
224 of your child?
- 225 - Where do you look for information on AHDS or MCT8 deficiency?
226 *Ask our doctor; Information flyers or leaflets; On the website mct8.info; On the*
227 *Facebook group for family members affected by MCT8 deficiency; Other internet*
228 *websites; Patient organization for MCT8 deficiency; A combination of all; Other*
- 229 - What is your opinion regarding the availability of information about AHDS or MCT8?
230 *Very bad; Bad; Sufficient; Good; Very good*
- 231 - What can be improved about the availability of information about AHDS or MCT8?
- 232 - How do you rate the level of knowledge about AHDS or MCT8 among medical professionals?
233 *Very bad; Bad; Sufficient; Good; Very good*
- 234 - What can be improved regarding the knowledge of AHDS or MCT8 among medical
235 professionals?
- 236 - Do you currently receive the AHDS or MCT8 newsletter?
- 237 - If yes, please provide your opinion about the newsletter?
- 238 - If no: Do you want to receive the newsletter in the future?

239 **Progression of symptoms**

- 240 - Please indicate the progression of the listed symptoms during the different age periods (in
241 years) on a scale from 0-4. (at ages 0-1, 1-2, 2-3, 3-4, 4-5, 5-6, 6-10, 11-15, 16-20, 21-30 and
242 +30)
- 243 ○ Increased muscle tone
- 244 ○ Seizures
- 245 ○ Swallowing difficulties
- 246 ○ Low body weight
- 247 ○ Sleeping problems

248 **Progression of development**

- 249 - Please note if your child has improved in the development of these listed skills during the
250 different age periods (in years) on a scale from 1-3. (at ages 0-1, 1-2, 2-3, 3-4, 4-5, 5-6, 6-10,
251 11-15, 16-20, 21-30 and +30)
- 252 ○ Communicative skills
- 253 ○ Social skills
- 254 ○ Motor skills

255 **Questionnaire for physicians**

256 The questionnaire for physicians consisted of the following sections. The questionnaire includes closed
257 questions (preset answer options: *yes, no, or no answer*; other preset answer options are shown in
258 *italic* below, where applicable) and open questions. For some questions, multiple present answers can
259 be chosen (indicated with o below). Explanatory information is provided in the system to further clarify
260 questions. Physicians can remark on their answers for a subset of questions. The section 'Evaluation
261 over time' includes user-friendly tables to enable easy data entry.

262 **General information**

- 263 - Date of birth of your patient?
- 264 - At what age has MCT8 deficiency been diagnosed (years and months)?
- 265 - MCT8 mutation
 - 266 ○ At DNA level:
 - 267 ○ At protein level:
 - 268 ○ Reference sequence that has been used:
- 269 - Have skin fibroblasts been collected?
- 270 - Has any data on your patient ever been published?
- 271 - If yes, please provide any of the following identifiers .
 - 272 ○ PMID:
 - 273 ○ DOI:
 - 274 ○ Reference:
- 275 - Are any other family members of your patient affected by MCT8 deficiency or carrier of the
276 MCT8 mutation?
- 277 - If yes, please specify who en what the relation to the child is.
- 278 - Upload a pedigree (if available).

279 **Perinatal information**

- 280 - APGAR score of the child after 1 minute?
- 281 - APGAR score of the child after 5 minutes?
- 282 - Birth weight of the child?
 - 283 ○ Grams:
 - 284 ○ Percentile:
 - 285 ○ SD-score:
- 286 - Birth height of the child?
 - 287 ○ Centimeters:
 - 288 ○ Percentile:
 - 289 ○ SD-score:
- 290 - Head circumference at birth of the child?
 - 291 ○ Centimeters:
 - 292 ○ Percentile:
 - 293 ○ SD-score:

294

295 **Feeding**

- 296 - Does the child aspirate any food or drinks?
- 297 - If yes, please specify?
 - 298 ○ Liquid
 - 299 ○ Thickened liquid
 - 300 ○ Smooth/pureed
 - 301 ○ Pieces/chopped
 - 302 ○ Solid
- 303 - Is a gastric tube present?
- 304 - If yes, please specify what kind of feeding tube is present?
 - 305 ○ PEG tube/ gastrostomy
 - 306 ○ Intranasal tube
 - 307 ○ Other
- 308 - Since what age is this feeding tube present? (years and months)
- 309 - Remarks

310 **Current situation**

- 311 - Dystonia?
 - 312 ○ Treatment:
- 313 - Spasticity?
 - 314 ○ Treatment:
- 315 - Seizures?
 - 316 ○ Treatment:
- 317 - Drooling?
 - 318 ○ Treatment:
- 319 - Constipation?
 - 320 ○ Treatment:
- 321 - Gastric reflux?
 - 322 ○ Treatment:
- 323 - Urinary incontinence?
- 324 - Sweating without or with minimal exercise?
- 325 - Hip luxation?
 - 326 ○ Treatment:
- 327 - Scoliosis?
 - 328 ○ Treatment:

329 **Evaluation over time**

- 330 - Overview of body weight (in kilograms) and height (in centimeters) over time (in years).
- 331 Measured at one timepoint within the indicated time frame. (0-1, 1-2, 2-3, 3-4, 4-5, 5-6, 6-10,
- 332 11-15, 16-20, 21-30, 30+)
 - 333 ○ Exact age (in years and months)
 - 334 ○ Weight
 - 335 ○ Height
- 336 - Please indicate the absence (0) or presence (1) of the symptoms below at indicated ages. If not
- 337 known or not applicable, the field can be left empty. (0-1, 1-2, 2-3, 3-4, 4-5, 5-6, 6-10, 11-15,
- 338 16-20, 21-30, 30+)
 - 339 ○ Dystonia
 - 340 ○ Spasticity
 - 341 ○ Seizures
 - 342 ○ Scoliosis

343 **Physical examination**

- 344 - Examination date
- 345 - Body weight?
- 346 - Body height?
- 347 - Head circumference?
- 348 - Describe dysmorphic features.
- 349 - Pulse rate (bpm)?
- 350 - Muscle volume (relative to patients of the same age with intellectual disability)?
351 *Less; Similar; More; No answer*
- 352 - Pectus excavatum?
- 353 - Tanner stage?
354 *I; II; III; IV; V; No answer*
- 355 - Most important way of interaction with you?
 - 356 ○ Sounds
 - 357 ○ Eye contact
 - 358 ○ Signs / physical contact
 - 359 ○ Speech computer
 - 360 ○ Speech
- 361 - Nystagmus?
- 362 - Please describe.
- 363 - Truncal hypotonia?
- 364 - Head drop?
- 365 - Patellar tendon reflex (left)?
366 *No response; Slight but definitively present; A brisk response; Very brisk response;*
367 *Pathologically brisk with clonus; No answer*
- 368 - Patellar tendon reflex (right)?
369 *No response; Slight but definitively present; A brisk response; Very brisk response;*
370 *Pathologically brisk with clonus; No answer*
- 371 - Plantar reflex according to Babinski (left)?
372 *Dorsiflexion (pathological); Plantar flexion; Indifferent; No answer*
- 373 - Plantar reflex according to Babinski (right)?
374 *Dorsiflexion (pathological); Plantar flexion; Indifferent; No answer*
- 375 - Contractures?
- 376 - Dystonia?
- 377 - Other dyskinetic movements (dyskinetic movement disorders)?
- 378 - Please specify.
- 379 - Tonic neck reflex?
380 *Present; Absent; Unknown; No answer*
- 381 - Glabellar sign?
382 *Present; Absent; Unknown; No answer*
- 383 - Muscle tone forelimp (MAS score)? (left and right)
- 384 - Indicate which motor milestone have been achieved by your patient.
 - 385 ○ Holds neck
 - 386 ○ Slips not through hands when lifted
 - 387 ○ Lifts head in prone position
 - 388 ○ Turns head in prone position
 - 389 ○ Rolls over (back to belly)
 - 390 ○ Rolls over (belly to back)
 - 391 ○ Sits without support
 - 392 ○ Gets to sit without support
 - 393 ○ Stands without support

- 394 ○ Stands without support
- 395 ○ Creeps
- 396 ○ Walks with support
- 397 ○ Walks without support
- 398 ○ Rides tricycle
- 399 ○ Jumps with both feet of the floor
- 400 - Select fine motor milestones that have been achieved by your patient.
- 401 ○ Fixates with eyes on object
- 402 ○ Grasps objects
- 403 ○ Grasps objects and puts in his mouth
- 404 ○ Moving object from one hand to the other
- 405 ○ Stacks bricks or other objects (max 3)
- 406 ○ Drinks from a cup
- 407 ○ Paints
- 408 - Select the communicative milestones that have been achieved by your patient.
- 409 ○ Crying
- 410 ○ Smiling
- 411 ○ Monotonic sounds
- 412 ○ Polytonic sounds
- 413 ○ Babbling
- 414 ○ Words
- 415 ○ Word combinations (max. 3 words)
- 416 ○ Sentences
- 417 - Are already achieved skills regressing over time?
- 418 - Please describe.
- 419 - Remarks and other findings?
- 420 **Historical diagnostics and evaluations**
- 421 - Has an MRI-cerebrum been performed in the past?

422 **Supplementary table 1**

Exemplary quotes from parents
Daily care challenges
<u>Mobility</u> : <i>"He is like a newborn baby in a larger body and could not hold his head."</i>
<u>Sleeping</u> : <i>"He wakes up screaming and cries very loud. He often arches his back and his body seems very stiff. While crying it sometimes seems like he holds his breath too long."</i>
<u>Communication</u> : <i>"He makes it clear with facial expressions whether he likes something or not, in addition, communication with icons works well. Also mumbling/making noise when he doesn't agree."</i>
Challenges in diagnostic trajectory
<u>Specialist care</u> : <i>"...Unfortunately, a referral to genetics was the last step on our path when it probably should have happened much earlier. We had a diagnosis within three weeks of seeing a geneticist, but it took us over a year to get to that point."</i>
<u>Thyroid function test evaluation</u> : <i>"They knew pretty fast what the diagnosis could be when they saw the testresult of the thyroid hormones."</i>
Improving the diagnostic process
<u>Disease awareness</u> : <i>"Spread information directly to neurology and endocrinology specialists at the major pediatric hospitals all over the world. Because it's known that as soon they diagnosticate the disease better are the chances for improvements in cognitive and motor skills."</i>
<u>Screening</u> : <i>"In [European country] doctors don't know the disease so we need to have prenatal screening and be able to talk about the disease to pediatricians to explain symptoms and to test children early."</i>

423 Exemplary quotes from parents.

424 **Supplementary table 2**

	Patients on Triac	Patient not on thyroid medication
Transpiration with little exercise (fraction)	5/18	4/10
Weight loss at infections/stress (fraction)	16/20	5/8
Difficulty to regain weight (fraction)	12/18	5/9
Easily agitated (fraction)	9/18	7/10
Frequent defecation (>4/day; fraction)	4/20	4/9
Difficulty falling asleep (>30 minutes; fraction)	7/18	5/8

425 Report of thyrotoxic symptoms of patients on treatment with thyroid hormone analogue Triac *versus*

426 patients who were not on any thyroid medication. Data are not expressed as percentage given the

427 low number of patients included in the analyses.

428 **Supplementary table 3**

	Patients with data on specialist care
Specialist (n=32)	
<i>(Paediatric) neurologist</i>	21 (66%)
<i>General paediatrician</i>	16 (50%)
<i>(Paediatric) endocrinologist</i>	14 (44%)
<i>Ophthalmologist</i>	9 (28%)
<i>(Paediatric) gastroenterologist</i>	6 (19%)
<i>Orthopaedic surgeon</i>	6 (19%)
<i>General practitioner</i>	5 (16%)
<i>Neuropsychiatrist</i>	3 (9%)
<i>ENT specialist</i>	2 (6%)
<i>Dentist</i>	2 (6%)
<i>Geneticist</i>	2 (6%)
<i>(Paediatric) specialist in metabolic diseases</i>	2 (6%)
<i>Revalidation specialist</i>	2 (6%)
<i>(Paediatric) cardiologist</i>	2 (6%)
<i>Osteopath</i>	2 (6%)
<i>Nutrologist</i>	2 (6%)
<i>Specialist for patients with intellectual and motor disability</i>	1 (3%)
<i>Developmental paediatrician</i>	1 (3%)
<i>(Paediatric) surgeon</i>	1 (3%)
<i>Multidisciplinary team</i>	3 (9%)


429 Data are n (%). Abbreviations: ENT, ear nose throat medicine.

430 **Supplementary table 4**

Specialist	Role & areas of attention	Frequency
(Paediatric) endocrinologist	<ul style="list-style-type: none"> - Follow-up of peripheral thyrotoxic signs - Follow-up of weight and growth - Initiation and follow-up of thyroid hormone analogue treatment - Follow-up and treatment of adverse events 	<ul style="list-style-type: none"> - Every 2-4 weeks during treatment initiation - Bi-annually on stable or no treatment
(Paediatric) neurologist	<ul style="list-style-type: none"> - Follow-up of brain development - Follow-up of movement disorders - Follow-up and treatment of epilepsy (by EEG) - Follow-up and treatment of drooling 	<ul style="list-style-type: none"> - Bi-annually
General paediatrician, general internist or general practitioner	<ul style="list-style-type: none"> - Coordination of complex needs 	<ul style="list-style-type: none"> - Bi-annually
(Paediatric) cardiologist	<ul style="list-style-type: none"> - Monitoring of cardiovascular abnormalities (specifically: PACs, bundle branch blocks and extended QTc by 24h Holter; aortic root size by TTE) and blood pressure 	<ul style="list-style-type: none"> - Annually
(Paediatric) gastroenterologist	<ul style="list-style-type: none"> - Follow-up and treatment of (treatment-resistant) gastro-esophageal reflux disease - Follow-up and treatment of (treatment-resistant) constipation - Installing feeding tube when appropriate 	<ul style="list-style-type: none"> - Annually
Orthopaedic surgeon	<ul style="list-style-type: none"> - Follow-up and treatment of scoliosis (patients >5 years) - Follow-up and treatment of hip luxation 	<ul style="list-style-type: none"> - On indication
Physical therapist	<ul style="list-style-type: none"> - Training of motor functions - Optimization of musculature status - Evaluation of gross motor functions (specifically: by GMFM-88) 	<ul style="list-style-type: none"> - Physical training: bi-weekly - GMFM-88: annually
Neuropsychologist	<ul style="list-style-type: none"> - Evaluation of neuropsychological functions (specifically: by BSID-III and VABS-II) 	<ul style="list-style-type: none"> - Annually
Speech therapist	<ul style="list-style-type: none"> - Optimization of swallowing functions 	<ul style="list-style-type: none"> - Weekly (without feeding tube) - Four times per year (with feeding tube)
Dietician and/or nutrologist	<ul style="list-style-type: none"> - Optimization of nutritional intake 	<ul style="list-style-type: none"> - Four times per year
Clinical chemist	<ul style="list-style-type: none"> - Interpretation of TFTs on thyroid hormone analogue therapy 	<ul style="list-style-type: none"> - On indication

- 431 Proposed design of a multidisciplinary team for MCT8 deficiency, with suggested roles, areas of attention and frequency per expertise. Abbreviations: EEG,
432 electroencephalogram; PAC, premature atrial complex; TTE, transthoracic echocardiogram; GMFM-88, Gross Motor Function Measure 88; BSID-III, Bailey
433 Scale of Infant Development III; VABS-II, Vineland Adaptive Behavior Scale II; TFT, thyroid function test

434 **Figure S1: Procedures of the International MCT8 Deficiency Registry**



- 1) Family signs up for MCT8 deficiency registry via <https://mct8registry.erasmusmc.nl/en>
- 2) Family is added to MCT8 deficiency registry and are requested to provide informed consent
- 3) Family provides informed consent; questionnaire for family becomes available and family receives unique token to provide to physician
- 4) Family provides unique token to physician
- 5) Physician registers in MCT8 deficiency registry
- 6) Physician receives access to questionnaire for physician
- 7) Answers from family and physicians are collected and used for research




435

436 **Figure S1:** Overview of the different steps in the International MCT8 Deficiency Registry. The
 437 requirement of a unique token for caregiving physicians ensures no data can be shared without full
 438 informed consent. Figure created with [BioRender.com](https://www.biorender.com/).

439


440 **Figure S2: Timeline of the design and implementation of the International MCT8 Deficiency**
441 **Registry**



442

443 **Figure S2:** Timeline of the design and implementation of the International MCT8 Deficiency Registry
444 and the MCT8-AHDS Foundation. Pivotal moments are shown in bold. Data regarding the MCT8-AHDS
445 Foundation was derived from mct8.info/about-us. Abbreviations: EURORDIS, European Organisation
446 for Rare Diseases.

447 **Figure S3: Difficulties in daily life after stratification for age**




448

449 **Figure S3: Difficulties in daily life care in patients <5 years (A) and ≥5 years of age (B). Numbers**

450 underlying the percentages are shown above the bars.


451 **Figure S4: Use of mobility aids upon aging**



452

453 **Figure S4: Parent-reported use of mobility aids, after stratification for age at registration.**

454 **Figure S5: Presenting symptoms**




455

456 **Figure S5:** First signs and symptoms observed by parents. Numbers underlying the percentages are


457 shown next to the bars.

458 **Figure S6: Difference in diagnostic delay between patients born before 2017 versus patients born in**
459 **or after 2017, after exclusion of patients born before 2004.**



460
461 **Figure S6: Parent-reported age of onset of symptoms and age of diagnosis in patients born before 2017**
462 **(upper panel) versus patients born in or after 2017 (lower panel), after exclusion of patients born**
463 **before October 2004.**

464 **Figure S7: Diagnostic delay per continent**



465 **Figure S7:** Median diagnostic delay after stratification for continent of residence at registration. Figure

466 created with [mapchart.net](https://www.mapchart.net/).

467 **References**

- 468 1. Friesema EC, Grueters A, Biebermann H, Krude H, von Moers A, Reeser M, et al. Association
469 between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation.
470 Lancet. 2004;364(9443):1435-7.
- 471 2. Dumitrescu AM, Liao XH, Best TB, Brockmann K, Refetoff S. A novel syndrome combining
472 thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter
473 gene. Am J Hum Genet. 2004;74(1):168-75.